Smokeless tobacco alternatives company Black Buffalo Inc announced on Tuesday that it has partnered with Sanova LLC, a New York-based scientific and regulatory consulting agency, to support its regulatory, compliance, and scientific research programmes.
Sanova has extensive experience helping nicotine manufacturers navigate complex regulatory frameworks, including the US Food and Drug Administration's (FDA) Premarket Tobacco Product Application (PMTA) and Modified Risk Tobacco Product (MRTP) pathways. Sanova's partnership with Black Buffalo includes helping guide the company through the final and most critical phases of FDA review, including substantive scientific review, a rigorous process that evaluates the health impact and overall safety profile of nicotine products intended for adult use.
Kellsi Booth, Black Buffalo's chief legal officer, said: "The Sanova team combines decades of FDA and industry insight with a forward-looking approach. Enlisting Sanova as a key partner represents our commitment to full regulatory transparency, scientific excellence, and responsible innovation within the nicotine space."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval